Cancer Genetics Announces Acquisition of NovellusDx to Expand its Oncology Platform
Shots:
- Cancer Genetics is acquiring NovellusDx by paying equity of ~49% in Cancer Genetics. NovellusDx will also provide $2. 3M bridge loan to Cancer Genetics
- Cancer Genetics will get hold of NovellusDx’s technology and machine learning capabilities for development of oncology drugs
- The acquisition will strengthen the focus on oncology precision medicines- and developing targeted therapeutics in cancer treatment. The transaction is expected to close in H1’19
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com